WGS
GeneDx Holdings Corp.
$65.64
-3.75 (-5.40%)
At close · Jul 10
Market Cap
$1.95B
Shares
29,688,027
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$65.64
Open$69.74
Day$64.84–69.75
52W$32.21–170.87
Avg vol 30d1.0M
Short int5.9M · 20.0% float · 5.9d
Short vol46%
Last earningsMay 4, 2026
DataNov 2020–Jul 2026
Filing10-Q · May 4
Up next
Next earnings call
Aug 3, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
+20%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
24%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
−40%
trailing
YTD return
−50%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $55 › 200d $95 — 200d above 50d
Institutional flow
Accumulating
8 of 244 funds reported for Jun 30 · net +200.5K sh shares
Insider flow
Accumulating
Net +$91.8M over 90 days · 50% sells
Short interest
Falling
20.01% of float · ▼ -1.2% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
244 holders — mid 3-yr range
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+40%
Y/Y
Gross margin
70%
expanding
EPS growth
+62%
Y/Y
Free cash flow
$14.3M
Balance sheet
$50.5M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 4, 2026
Full Year 2026
Revenue
Maintained
$475M – $490M
prior FY $427.54M
midpoint +12.9% Y/Y
Growth in exome and genome volume
Initiated
at least 30%
Growth in exome and genome revenue
Initiated
at least 20%
Adjusted gross margin
Non-GAAP
Initiated
at least 70%
Second Quarter of 2026
Revenue
Initiated
$110M – $112M
prior qtr $102.25M
midpoint +8.6% QoQ
Growth in exome and genome revenue
at least $100M
prior qtr $102.25M
midpoint −2.2% QoQ
Adjusted gross margin
Non-GAAP
Initiated
at least 70%
Adjusted net loss
Non-GAAP
Initiated
$-5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
+20%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
24%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $55 › 200d $95 — 200d above 50d
Institutional flow
Accumulating
8 of 244 funds reported for Jun 30 · net +200.5K sh shares
Insider flow
Accumulating
Net +$91.8M over 90 days · 50% sells
Short interest
Falling
20.01% of float · ▼ -1.2% MoM · 5.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
244 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $32
Now $66 · 24%
52-wk high $171
vs 200-day avg -31%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted gross margin non-GAAP | 69% | first quarter 2026 | — |
|
|
|||
| Adjusted net loss non-GAAP | $8.2M | first quarter 2026 | — |
| Adjusted total operating expenses non-GAAP | $78.1M | first quarter 2026 | — |
|
|
|||
| Exome and genome test result volume | 27,488 | first quarter 2026 | — |
|
|
|||
| blended average reimbursement rate | $3,300 | first quarter call | — |
| exome and genome revenue | $90.6M | first quarter call | — |
| exome and genome revenue growth | 27% | first quarter call | — |
| exome and genome volume | 34% | Q1 call | — |
| matched phenotypic profiles | 8M | Mar 31, 2026 call | — |
| patients in database | 2.5M | Mar 31, 2026 call | — |
| state Medicaid programs covering test | 38 | Mar 31, 2026 call | — |
| test result volume | 27,488 | first quarter call | — |
| Adjusted net income non-GAAP | $41.8M | Full year 2025 | — |
| Exome and genome represented of all test results | 43% | Full year 2025 | — |
| Exome and genome test results volume | 97,271 | Full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WGS
this stock
GeneDx Holdings Corp.
|
$1.95B | -49.5% | +0.0% | — | 20.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$195.86B | -9.0% | +0.4% | 29.0 | 1.4% |
|
DHR
Danaher Corp /De/
|
$140.88B | -12.7% | +8.5% | 38.4 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.46B | -16.7% | +10.4% | 41.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.66B | +17.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WGS | -2.8% | +20.8% | -39.9% | -4.4% | -49.5% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -4.1% | +16.8% | -49.0% | -5.5% | -60.2% |